HUP0103622A2 - Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0103622A2 HUP0103622A2 HU0103622A HUP0103622A HUP0103622A2 HU P0103622 A2 HUP0103622 A2 HU P0103622A2 HU 0103622 A HU0103622 A HU 0103622A HU P0103622 A HUP0103622 A HU P0103622A HU P0103622 A2 HUP0103622 A2 HU P0103622A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- substituted
- atoms
- unsubstituted alkyl
- alkynyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000000543 intermediate Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 101150108262 gnrh1 gene Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000003270 steroid hormone Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A tal lm ny a gonadotropin-leadó hormon hat s t g tló nem peptidtípusú GnRH hatóanyagokra vonatkozik. Az (I) ltal nos képletűvegyületek, gyógy szatilag elfogadható sóik, multimerjeik,elővegyületeik és aktív metabolitjaik emlős"k reprodukciósrendellenességei, szteroid hormonfüggő tumorok kezelésére és atermékenység szab lyoz s ra haszn lhatók. A tal lm ny a vegyületek elő llít s ra szolg ló elj r sokat és azelj r sokban haszn lt intermediereket is mag ban foglalja és kiterjeda vegyületeket tartalmazó gyógyszerkészítményekre is. Az (I) ltal nosképletben X jelentése C=O, C=S, S=O és S(O)2; (het) jelentése 5 tagúheterociklusos gyűrű, amely 1-4, előny"sen 2-3 heteroatomot tartalmaz,amely nitrogénatom, oxigénatom vagy kénatom lehet, és ahol a gyűrűlehet telített, részben telítetlen, teljesen telítetlen vagy arom s;R1 és R2 jelentése egym stól függetlenül hidrogénatom vagy kisszénatomsz mú alkilcsoport; R3 jelentése hidrogénatom, halogénatom,szubsztitu lt vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentéseszubsztitu lt vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril- vagyheteroarilcsoport, ahol a szénatomok sz m nak "sszege, az adottesetben jelenlevő szubsztituenseket nem sz mítva, 1-12; R4 és R5jelentése egym stól függetlenül hidrogénatom, halogénatom, szubsztitult vagy szubsztitu latlan alkil-, alkenil-, alkinil-,cikloalkilcsoport, heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentése afentiekben meghat rozott, R6 és R7 jelentése egym stól függetlenülhidrogénatom, halogénatom, szubsztitu lt vagy szubsztitu latlanalkil-, alkenil-, alkinil-, cikloalkilcsoport, heterociklusos csoport,aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletűcsoport, ahol R jelentése a fentiekben meghat rozott, és ahol aszénatomok sz m nak "sszege, az adott esetben jelen levőszubsztituenseket nem sz mítva, 1-12; vagy R6 és R7 a kapcsolódóatomokkal együtt egy adott esetben szubsztitu lt 5-6 tagú gyűrűtalkot, amelyek 5-7 heteroatomot tartalmazhatnak, amelyek nitrogén-,oxigén- vagy kénatomok lehetnek; R8 jelentése lipofil csoport, amelyeta k"vetkezőkben felsoroltak k"zül v laszthatunk: szubsztitu lt vagyszubsztitu latlan alkil-, alkenil-, alkinil-, cikloalkilcsoport,heterociklusos csoport, aril-, heteroarilcsoport, -CH2OR, -OR vagy -C(O)OR ltal nos képletű csoport, ahol R jelentése a fentiekben meghatrozott, és ahol a szénatomok sz m nak "sszege, az adott esetben jelenlevő szubsztituenseket nem sz mítva, 6-20; R9 jelentése hidrogénatomvagy szubsztitu lt vagy szubsztitu latlan alkilcsoport, előny"senkisszénatomsz mú
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9752098P | 1998-08-20 | 1998-08-20 | |
| PCT/US1999/018790 WO2000020358A2 (en) | 1998-08-20 | 1999-08-20 | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0103622A2 true HUP0103622A2 (hu) | 2002-04-29 |
| HUP0103622A3 HUP0103622A3 (en) | 2003-01-28 |
Family
ID=22263796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103622A HUP0103622A3 (en) | 1998-08-20 | 1999-08-20 | Non-peptide gnrh agents, methods and intermediates for their preparation and medicaments containing them |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1105120B1 (hu) |
| JP (1) | JP2002535244A (hu) |
| KR (1) | KR20010085402A (hu) |
| CN (1) | CN1379666A (hu) |
| AP (1) | AP2001002053A0 (hu) |
| AT (1) | ATE291423T1 (hu) |
| AU (1) | AU759310B2 (hu) |
| BG (1) | BG105362A (hu) |
| BR (1) | BR9913374A (hu) |
| CA (1) | CA2341346A1 (hu) |
| CZ (1) | CZ2001523A3 (hu) |
| DE (1) | DE69924387D1 (hu) |
| EA (1) | EA200100255A1 (hu) |
| EE (1) | EE200100102A (hu) |
| ES (1) | ES2237966T3 (hu) |
| GE (1) | GEP20043315B (hu) |
| HR (1) | HRP20010206A2 (hu) |
| HU (1) | HUP0103622A3 (hu) |
| ID (1) | ID29244A (hu) |
| IL (1) | IL141396A0 (hu) |
| IS (1) | IS5846A (hu) |
| LT (1) | LT4904B (hu) |
| LV (1) | LV12732B (hu) |
| NO (1) | NO20010309L (hu) |
| NZ (1) | NZ509252A (hu) |
| OA (1) | OA11599A (hu) |
| PL (1) | PL356984A1 (hu) |
| SI (1) | SI20746A (hu) |
| SK (1) | SK2262001A3 (hu) |
| TR (1) | TR200100631T2 (hu) |
| WO (1) | WO2000020358A2 (hu) |
| YU (1) | YU13701A (hu) |
| ZA (1) | ZA200100831B (hu) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195716T1 (de) * | 1992-04-22 | 2000-09-15 | Ligand Pharm Inc | Retinoid-x rezeptor selektive verbindungen |
| AU775123B2 (en) * | 1999-03-24 | 2004-07-15 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
| AR024158A1 (es) * | 1999-06-01 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| EP1401427A4 (en) * | 2001-06-06 | 2004-12-01 | Agouron Pharma | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF |
| AU2002344854B2 (en) | 2001-06-11 | 2008-11-06 | Vertex Pharmaceuticals (Canada) Incorporated | Thiophene derivatives as antiviral agents for flavivirus infection |
| JP4445262B2 (ja) | 2001-10-09 | 2010-04-07 | アムジェン インコーポレイテッド | 抗炎症剤としてのイミダゾール誘導体 |
| GB0126292D0 (en) * | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| JP2005170790A (ja) * | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| US6521395B1 (en) * | 2002-01-30 | 2003-02-18 | Eastman Kodak Company | Infrared couplers for incorporating and recovering metadata |
| AU2003202115A1 (en) * | 2002-02-12 | 2003-09-04 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| CA2489252A1 (en) * | 2002-06-13 | 2003-12-24 | Pfizer Inc. | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use |
| DE60307313T2 (de) * | 2002-11-20 | 2006-12-14 | Paradigm Therapeutics Ltd. | Heterozyklische siliziumverbindungen und deren verwendung zur behandlung von krankheiten oder zuständen, die mit gnrh (gonadotropinfreisetzendem hormon) assoziiert sind |
| ZA200507112B (en) * | 2003-03-31 | 2007-03-28 | Taisho Pharmaceutical Co Ltd | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| CA2536964A1 (en) * | 2003-04-25 | 2004-11-11 | Ortho-Mcneil Pharmaceutical, Inc. | C-fms kinase inhibitors |
| WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| BRPI0412360A (pt) * | 2003-07-09 | 2006-09-05 | Paradigm Therapeutics Ltd | compostos de organossilìcio e seu uso |
| AU2004255912B2 (en) | 2003-07-10 | 2008-05-01 | Paradigm Therapeutics Ltd. | Silicon compounds and their use |
| US20050182061A1 (en) * | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
| US20090291915A1 (en) * | 2004-12-17 | 2009-11-26 | Graham Andrew Showell | Silicon Compounds and Their Use |
| KR20080016597A (ko) | 2005-05-13 | 2008-02-21 | 바이로켐 파마 인코포레이티드 | 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법 |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| EP1890703B1 (en) | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
| WO2007000582A1 (en) * | 2005-06-28 | 2007-01-04 | Takeda Cambridge Limited | Heterocyclic non-peptide gnrh antagonists |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| WO2007131996A1 (en) * | 2006-05-12 | 2007-11-22 | Genmedica Therapeutics Sl | Meta-xylylenediamine vanadate salts |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| AU2008310660A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| CN101888991A (zh) * | 2007-10-31 | 2010-11-17 | 财团法人乙卯研究所 | 类视色素前体药物化合物 |
| WO2009131598A1 (en) | 2008-04-21 | 2009-10-29 | Taigen Biotechnology Co., Ltd. | Heterocyclic compounds |
| UY31984A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| SG187209A1 (en) | 2010-08-05 | 2013-03-28 | Amgen Inc | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| CN102050823A (zh) * | 2010-10-27 | 2011-05-11 | 华东理工大学 | 新型光稳定剂-鸟嘌呤类似物的合成及表征 |
| WO2012112567A1 (en) * | 2011-02-15 | 2012-08-23 | Georgetown University | Small molecule inhibitors of agbl2 |
| US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| CA2841905A1 (en) * | 2011-07-26 | 2013-01-31 | Sanofi | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| WO2013067578A1 (en) * | 2011-11-07 | 2013-05-16 | The University Of Queensland | Modulators of c3a receptors |
| IN2015DN03969A (hu) | 2012-10-17 | 2015-10-02 | Univ Bristol | |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| WO2017070235A1 (en) * | 2015-10-19 | 2017-04-27 | Attenua, Inc. | Antitussive compositions and methods |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3499002A (en) * | 1968-06-20 | 1970-03-03 | Robins Co Inc A H | 1-carbamoyl-3-aroylpyrrolidines |
| NL6913261A (hu) * | 1968-09-09 | 1970-03-11 | ||
| US3932444A (en) * | 1972-04-28 | 1976-01-13 | E. I. Du Pont De Nemours & Co. | 4-Imidazolylsulfonylimidazoles |
| US4013647A (en) * | 1976-03-23 | 1977-03-22 | American Home Products Corporation | Morpholine containing tetrazole-5-carboxamide derivatives |
| GB1491776A (en) * | 1976-09-08 | 1977-11-16 | Pfizer Ltd | Thiadiazoles |
| US4096153A (en) * | 1977-01-21 | 1978-06-20 | American Home Products Corporation | Arylene-bis-tetrazole-5-carboxamides |
| US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
| EP0592512A1 (en) | 1991-07-01 | 1994-04-20 | University Technologies International Inc. (Uti) | NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS |
| JPH07502529A (ja) * | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
| DE69628705T2 (de) * | 1995-08-24 | 2004-05-13 | Basf Ag | Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide |
| EP0882040A4 (en) * | 1995-12-14 | 1999-02-10 | Merck & Co Inc | GONADOLIBERIN ANTAGONISTS |
| EP0901489A1 (en) * | 1996-05-20 | 1999-03-17 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5878393A (en) * | 1996-09-09 | 1999-03-02 | Matsushita Electric Industrial Co., Ltd. | High quality concatenative reading system |
-
1999
- 1999-08-20 OA OA1200100043A patent/OA11599A/en unknown
- 1999-08-20 SI SI9920076A patent/SI20746A/sl not_active IP Right Cessation
- 1999-08-20 WO PCT/US1999/018790 patent/WO2000020358A2/en not_active Application Discontinuation
- 1999-08-20 JP JP2000574479A patent/JP2002535244A/ja active Pending
- 1999-08-20 TR TR2001/00631T patent/TR200100631T2/xx unknown
- 1999-08-20 PL PL99356984A patent/PL356984A1/xx unknown
- 1999-08-20 IL IL14139699A patent/IL141396A0/xx unknown
- 1999-08-20 ES ES99968010T patent/ES2237966T3/es not_active Expired - Lifetime
- 1999-08-20 AP APAP/P/2001/002053A patent/AP2001002053A0/en unknown
- 1999-08-20 ID IDW20010406A patent/ID29244A/id unknown
- 1999-08-20 HU HU0103622A patent/HUP0103622A3/hu unknown
- 1999-08-20 YU YU13701A patent/YU13701A/sh unknown
- 1999-08-20 CA CA002341346A patent/CA2341346A1/en not_active Abandoned
- 1999-08-20 DE DE69924387T patent/DE69924387D1/de not_active Expired - Fee Related
- 1999-08-20 BR BR9913374-1A patent/BR9913374A/pt not_active IP Right Cessation
- 1999-08-20 KR KR1020017002021A patent/KR20010085402A/ko not_active Application Discontinuation
- 1999-08-20 CN CN99812285A patent/CN1379666A/zh active Pending
- 1999-08-20 AT AT99968010T patent/ATE291423T1/de not_active IP Right Cessation
- 1999-08-20 NZ NZ509252A patent/NZ509252A/en unknown
- 1999-08-20 EA EA200100255A patent/EA200100255A1/ru unknown
- 1999-08-20 EE EEP200100102A patent/EE200100102A/xx unknown
- 1999-08-20 EP EP99968010A patent/EP1105120B1/en not_active Expired - Lifetime
- 1999-08-20 AU AU24709/00A patent/AU759310B2/en not_active Ceased
- 1999-08-20 SK SK226-2001A patent/SK2262001A3/sk unknown
- 1999-08-20 CZ CZ2001523A patent/CZ2001523A3/cs unknown
- 1999-08-20 GE GE4368A patent/GEP20043315B/en unknown
-
2001
- 2001-01-19 NO NO20010309A patent/NO20010309L/no not_active Application Discontinuation
- 2001-01-30 ZA ZA200100831A patent/ZA200100831B/en unknown
- 2001-02-16 IS IS5846A patent/IS5846A/is unknown
- 2001-03-16 LV LVP-01-45A patent/LV12732B/en unknown
- 2001-03-19 BG BG105362A patent/BG105362A/xx unknown
- 2001-03-19 LT LT2001024A patent/LT4904B/lt unknown
- 2001-03-20 HR HR20010206A patent/HRP20010206A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0103622A2 (hu) | Nem peptid típusú GnRH hatóanyagok és az előállításukra szolgáló módszerek és intermedierek és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0105113A2 (hu) | Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0102543A2 (hu) | Szexuális rendellenességek kezelésére alkalmas, cGMP PDE inhibitor hatású pirazolopiramidinon-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203971A2 (hu) | Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0004845A2 (hu) | PPAR-gamma agonista aktivitással rendelkező szubsztituált 4-hidroxi-fenil-alkánsav-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0104867A2 (hu) | Gyulladásos betegségek kezelésére használható heterociklusos vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP0203895A2 (hu) | Szubsztituált azaindolok és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| MY102866A (en) | Amide derivatives. | |
| HUP0004400A2 (hu) | Dipeptid-nitrilek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0302475A2 (hu) | Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával | |
| HUP0100280A2 (hu) | Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények | |
| NO306778B1 (no) | Heterocyklisk aromatisk oksazolforbindelse, mellomprodukter, farmasöytiske preparater inneholdende forbindelsene, rene cyklooksagenase-2 inhibitorer samt et antiinflammatorisk middel | |
| HUP0202017A2 (hu) | Új vegyületek | |
| KR890008155A (ko) | 신규인 유도체, 그 제조방법 및 의약에서의 사용 | |
| KR910011895A (ko) | 약제 | |
| HUP0105204A2 (hu) | Helyettesített fenetil-amin-származékok és ezeket tartalmazó gyógyászati készítmények | |
| HUP0103921A2 (hu) | [1,2,4]triazolo[1,5-c]pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| NO800447L (no) | Derivater av difenylhydantoin, farmasoeytiske preparater inneholdende slike preparater, samt fremgangsmaate til fremstilling av de aktive forbindelser | |
| HUP0103072A2 (hu) | Növekedési hormon kiválasztást elősegítő vegyületek alkalmazása | |
| HUP0102500A2 (hu) | Növekedési hormon szekretagógok alkalmazása szisztémás lupus erythematosus és gyulladásos bélbetegség kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0100184A2 (hu) | Szubsztituált 2-(benzil-amino)-2-fenil-acetamid-vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203787A2 (hu) | Hidroxi-acetil-piperazinnal szubsztituált oxazolidinon-benzoesav-észterek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ES8207124A1 (es) | Un procedimiento para la preparacion de derivados de aminas secundarias. | |
| HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények |